Φορτώνει......
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isola...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Oncoimmunology |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Taylor & Francis
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8216182/ https://ncbi.nlm.nih.gov/pubmed/34235003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1936757 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|